Royalty Pharma PLC RPRX
58.21
0.56
0.97%
as of 25 Sep
- Market cap
- $34.4B
- P/E
- 40.1×
Follow RPRX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
38.67 | 32.63 | 28.62 | 26.73 |
+8 more quarters Free account |
P/S ratio |
9.84 | 8.59 | 6.98 | 6.48 | |
P/FCF ratio |
19.05 | 17.53 | 4.72 | 4.44 | |
P/Operating CF |
34.26 | 29.17 | 20.08 | 21.69 | |
P/B ratio |
2.55 | 2.11 | 1.71 | 1.58 | |
Price to Tangible BV |
2.82 | 2.32 | 1.89 | 1.75 | |
EV/Sales |
13.04 | 12.01 | 10.48 | 9.88 | |
EV/EBITDA |
21.38 | 18.04 | 15.65 | 14.87 | |
EV/Operating CF |
11.11 | 11.22 | 10.01 | 9.66 | |
EV/FCF |
25.25 | 24.51 | 7.09 | 6.77 | |
Quick Ratio |
1.38 | 1.19 | 1.05 | 1.85 | |
Current Ratio |
2.80 | 2.66 | 2.40 | 3.48 | |
Net Debt/EBITDA |
57.16 | 14.60 | 20.93 | 18.32 | |
Debt/Assets |
45.22% | 45.20% | 45.62% | 46.24% | |
Debt/Equity |
0.92 | 0.90 | 0.92 | 0.93 | |
Asset Turnover |
0.13 | 0.13 | 0.13 | 0.13 | |
Operating CF/Net income |
40.73 | 2.44 | 3.92 | 2.44 | |
Capex/Depreciation |
(27.81) | (51.17) | 0.00 | (105.46) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
14.51% | 6.31% | 8.12% | 8.29% | |
Selling, General and Administrative Expense of Revenue |
24.01% | 25.29% | 26.41% | 19.49% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
15.88% | 19.35% | 20.22% | 11.96% | |
Graham Net Nets |
(0.33) | (0.40) | (0.50) | (0.52) | |
Graham Number |
26.78 | 27.43 | 26.20 | 25.72 | |
Earnings Yield |
2.59% | 3.06% | 3.49% | 3.74% | |
Free Cash Flow Yield |
5.25% | 5.71% | 21.18% | 22.53% | |
Revenue per Share |
1.51 | 1.44 | 1.45 | 1.41 | |
Operating CF per Share |
1.64 | 1.64 | 1.92 | 1.63 | |
Capex per Share |
(0.56) | (1.04) | 0.00 | (2.23) | |
Free Cash Flow per Share |
1.07 | 0.61 | 1.92 | (0.60) | |
Cash per Share |
1.88 | 1.39 | 1.48 | 2.21 | |
Shareholders Equity per Share |
21.99 | 22.75 | 22.60 | 22.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.99 | 22.75 | 22.60 | 22.28 | |
Free Cash Flow |
477.44 | 265.87 | 827.15 | (259.26) | |
Working Capital |
1,133.64 | 890.13 | 891.88 | 1,318.74 | |
Capital Expenditures |
(251.02) | (452.37) | — | (961.87) | |
Net Current Asset Value |
(8,269.49) | (8,452.77) | (8,377.75) | (7,876.88) | |
EV/EBIT |
21.88 | 18.45 | 15.98 | 15.16 | |
Capex to Sales |
0.37 | 0.72 | 0.00 | 1.58 | |
Net Profit Margin |
2.65% | 46.73% | 33.96% | 47.30% | |
Price to Operating Income |
16.51 | 13.19 | 10.65 | 9.94 | |
| Other line items | |||||
Average Receivables |
29.61 | 25.65 | 28.14 | 26.90 | |
Average Payables |
27.89 | 31.56 | 16.39 | 31.74 | |
Average Assets |
19,071.39 | 18,711.84 | 18,921.75 | 18,694.76 | |
Average Common Equity |
9,644.33 | 9,862.75 | 10,028.65 | 9,939.67 |
Columns are period end dates